UroGen Shorts Retreat as Earnings Loom

Short sellers have been cutting exposure to URGN at a meaningful pace, with short interest falling 30% from its October highs even as the stock gives back some of this year's gains ahead of its November 10 earnings release.

The unwinding has been rapid. Short interest peaked near 7.7 million shares in mid-October, representing roughly 16% of the free float. By November 3 it had dropped to 5.28 million shares, or 11.3% of float, a 17% decline in the final two weeks of October alone and a 16.6% fall over the past month. The lending market reflects the same shift: availability has surged to 1,173% of short interest from a 52-week low of 27%, meaning the pool of shares available to borrow dwarfs the number currently lent out. Cost to borrow collapsed to 0.18% from above 0.59% a week earlier, the lowest in the 30-day lookback. Options traders are pointing the same direction. The put/call ratio has dropped to 0.44, below its 20-day average of 0.54 and near the lower end of its 52-week range of 0.18 to 0.89. That is a less defensive posture than October, when the PCR was running above 0.73 during the period of heaviest short interest.

The Street remains firmly constructive, though the most recent analyst action is a few months old. Following the August quarterly results, three firms raised price targets: Guggenheim moved to $58, HC Wainwright to $75, and TD Cowen to $60. Those targets imply 74% to 118% upside against the current price of $34.40, a wide gap that reflects genuine disagreement between where the stock is trading and where analysts peg fair value. HC Wainwright reiterated its $75 Buy in mid-October. The bull case rests on ZUSDURI's commercial momentum, with 73% sequential net sales growth in the second quarter to $50.4 million, expanding to 1,444 activated sites of care. Bears point to a narrow commercial base, execution risk on the UGN-103 NDA (PDUFA date June 2027), and dilution risk. EPS momentum ranks in the 98th percentile over 90 days and the 92nd percentile over 30 days, suggesting estimates have been moving sharply higher. The PE multiple has compressed nearly six points over the past month to 15, while EV/EBITDA has edged down to 14.5, both moving in the direction of the bears' valuation concern easing.

One item on the activist register is worth noting. Fred Cohen filed a Schedule 13D/A in June 2025, declaring an activist stake then representing about 1.9% of the class. That filing is now well over a year old, and per the standard caveat on 13D/G disclosures, positions are as-last-disclosed around the 5% threshold and can change without a further filing. Separately, RA Capital, which held 7% as recently as May 2025, filed a 13G/A in August 2025 showing a position of zero, a clean exit that removed a significant healthcare specialist from the register. BlackRock filed a 13G/A on October 27 raising its disclosed stake to 6.3% from 5.2%, adding a large passive buyer to the picture.

Insider activity over the 90 days to October 8 shows net open-market selling of roughly $3 million across 65,000 shares. The largest single transaction was the CMO selling 60,677 shares at $47.05 in August, worth $2.85 million and not conducted under a 10b5-1 plan. The CFO sold 2,202 shares at $36.69 in early October, also outside a plan. The stock has fallen from those September highs near $42 to the current $34.40, a 17% decline over the past month that has brought it back toward the range where the CFO transacted. The ORTEX short score has also been falling alongside short interest, dropping from 69 in late October to 54.9 today, its lowest reading in the recent series, consistent with the broader easing in bearish positioning.

The November 10 earnings release is the near-term data point that will test whether the current retreat in short interest reflects genuine conviction or simply positioning ahead of a volatile catalyst.